- ISIN
- US4523271090
- CUSIP
- 452327109
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Jul 28, 2000
Highlights
- Market Cap
- $25.03B
- Enterprise Value
- $26.91B
- EPS (TTM)
- $5.48
- PE Ratio
- 29.68
- PEG Ratio
- 14.26
- Total Revenue (TTM)
- $4.39B
- Gross Profit (TTM)
- $2.93B
- EBITDA (TTM)
- $1.39B
- Year Range
- $81.76 - $165.97
- Target Price
- $147.13
- ROA (TTM)
- 13.01%
- ROE (TTM)
- 28.17%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ILMN Performance Chart
Illumina, Inc. (ILMN) is up 23.9% since the beginning of the year. At $163 per share, ILMN is trading just below its 52-week high of $166. Investors who bought $1,000 worth of ILMN shares 5 years ago would now be looking at an investment worth $413.
Loading charts...
Returns By Period
Illumina, Inc. (ILMN) has returned 23.93% so far this year and 100.46% over the past 12 months. Over the last ten years, ILMN has returned 1.39% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.
Illumina, Inc.
- 1D
- -1.13%
- 1M
- 19.72%
- YTD
- 23.93%
- 6M
- 27.44%
- 1Y
- 100.46%
- 3Y*
- -6.93%
- 5Y*
- -16.21%
- 10Y*
- 1.39%
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
ILMN Monthly Returns History
Based on dividend-adjusted daily data since Jul 28, 2000, ILMN's average daily return is +0.10%, while the average monthly return is +1.91%. At this rate, an investment would double in approximately 3.1 years.
Historically, 57% of months were positive and 43% were negative. The best month was May 2003 with a return of +73.4%, while the worst month was Mar 2001 at -52.9%. The longest winning streak lasted 16 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ILMN closed higher 51% of trading days. The best single day was Jan 25, 2012 with a return of +46.3%, while the worst single day was Oct 7, 2011 at -31.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 10.41% | -7.15% | -8.33% | 2.82% | 28.58% | -0.25% | 23.93% | ||||||
| 2025 | -0.67% | -33.15% | -10.59% | -2.19% | 5.98% | 16.01% | 7.65% | -2.68% | -4.99% | 30.08% | 6.40% | -0.22% | -1.85% |
| 2024 | 2.71% | -2.22% | -1.80% | -10.39% | -15.25% | 2.90% | 17.46% | 7.18% | -0.75% | 10.53% | 0.01% | -7.30% | -1.34% |
| 2023 | 5.93% | -7.00% | 16.74% | -11.61% | -4.33% | -4.66% | 2.49% | -14.02% | -16.91% | -20.29% | -6.83% | 36.58% | -31.14% |
| 2022 | -8.31% | -6.37% | 6.98% | -15.10% | -19.27% | -23.02% | 17.53% | -6.94% | -5.38% | 19.93% | -4.69% | -7.28% | -46.85% |
| 2021 | 15.25% | 3.04% | -12.60% | 2.29% | 3.26% | 16.66% | 4.76% | -7.78% | -11.28% | 2.33% | -11.98% | 4.14% | 2.82% |
Benchmark Metrics
Illumina, Inc. has an annualized alpha of 15.72%, beta of 1.14, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since July 31, 2000.
- This stock captured 193.84% of S&P 500 Index gains and 154.29% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.72%
- Beta
- 1.14
- R²
- 0.15
- Upside Capture
- 193.84%
- Downside Capture
- 154.29%
Return for Risk
Risk / Return Rank
ILMN ranks 87 for risk / return — in the top 87% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Illumina, Inc. (ILMN) and compare them to S&P 500 Index.
| ILMN | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.16 | 2.39 | -0.22 |
Sortino ratioReturn per unit of downside risk | 3.10 | 3.25 | -0.15 |
Omega ratioGain probability vs. loss probability | 1.38 | 1.43 | -0.06 |
Calmar ratioReturn relative to maximum drawdown | 3.94 | 3.11 | +0.82 |
Martin ratioReturn relative to average drawdown | 8.92 | 14.38 | -5.46 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Illumina, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Illumina, Inc. was 96.14%, occurring on Mar 13, 2003. Recovery took 1100 trading sessions.
The current Illumina, Inc. drawdown is 68.16%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2003 bear market2003 | -96.14%Mar 2003 | 2y 6mo | 4y 4mo | 6y 10moSep 2000 - Jul 2007 |
2025 selloff2025 | -86.23%Apr 2025 | 3y 7mo | — | 4y 9moAug 2021 - now |
2011 bear market2011 | -66.67%Dec 2011 | 5mo 9d | 1y 7mo | 2y 18dJul 2011 - Jul 2013 |
Financial crisis2007–2009 | -57.85%Nov 2008 | 3mo 5d | 1y 8mo | 1y 11moAug 2008 - Aug 2010 |
2016 bear market2016 | -49.16%Dec 2016 | 1y 4mo | 1y 1mo | 2y 5moJul 2015 - Jan 2018 |
Drawdown Indicators
| ILMN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.14% | -56.78% | -39.36% |
Max Drawdown (1Y)Largest decline over 1 year | -25.66% | -9.10% | -16.56% |
Max Drawdown (3Y)Largest decline over 3 years | -65.68% | -18.90% | -46.78% |
Max Drawdown (5Y)Largest decline over 5 years | -86.23% | -25.43% | -60.80% |
Max Drawdown (10Y)Largest decline over 10 years | -86.23% | -33.92% | -52.31% |
Current DrawdownCurrent decline from peak | -68.16% | 0.00% | -68.16% |
Average DrawdownAverage peak-to-trough decline | -40.37% | -10.72% | -29.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.30% | 1.97% | +9.33% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Illumina, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Illumina, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ILMN, comparing it with other companies in the Diagnostics & Research industry. Currently, ILMN has a P/E ratio of 29.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ILMN compared to other companies in the Diagnostics & Research industry. ILMN currently has a PEG ratio of 14.3. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ILMN relative to other companies in the Diagnostics & Research industry. Currently, ILMN has a P/S ratio of 5.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ILMN in comparison with other companies in the Diagnostics & Research industry. Currently, ILMN has a P/B value of 8.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ILMN
Add Illumina, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ILMN